Introduction
============

Tumors of the central nervous system (CNS) represent about 2% of all cancers. Gliomas account for ≥70% of all brain tumors [@B1]. In Iraq, as published in the cancer registry, CNS tumors are the fifth most common tumor in adults and the second most common in children. The exact etiology of glioma remains unclear [@B2]. The most important established environmental risk factor for gliomas and meningiomas is ionizing radiation exposure to the head and neck [@B3]. Inherited syndromes such as neurofibromatosis 1 and 2, tuberous sclerosis, Li-Fraumeni syndrome, and Turcot syndrome can also increase risk of both malignant and benign brain tumors, as well as for other cancers [@B4]. Several studies have examined the effects of single nucleotide polymorphisms (SNPs) in inflammation-associated genes on the risk of developing glioma, focusing on their potential role in survival. Certain SNPs in cytokine genes affect the expression of corresponding cytokines and therefore may interfere with individuals\' susceptibility to different type of malignancies [@B5].

Interleukin (IL)-10 is an important anti-inflammatory cytokine secreted by various cells of the immune system [@B6]. IL-10 inhibits the production of pro-inflammatory cytokines such as IL-1, IL-6, IL-12, IL-18 and TNF-α, as well as co-stimulatory molecules on antigen-presenting cells (APCs) [@B7]. High serum levels of IL-10 have suppressive roles in tumor-specific immunity and could reduce tumor growth [@B7]-[@B9]. Three single SNPs have been confirmed in the promoter region of IL-10; the most important is -1082 A\>G (rs1800869). Respectively, alleles A and G of this SNP seem to be associated with low and high levels of IL-10 production [@B10]. Several recent studies have shown that this SNP increases the susceptibility to digestive cancer, schizophrenia, gastric cancer, type-2 diabetes mellitus, and thyroid cancer [@B11]-[@B15].

Interleukin-12 (IL-12) is a disulphide-linked heterodimer composed of a light chain of 35kDa (IL-12A) and a heavy chain of 40kDa, which are encoded by separated genes [@B16]. The anti-tumor and anti-metastatic activities of IL-12 have been extensively examined in a variety of murine tumor models and found to delay, reduce and, in some cases, prohibit tumor development [@B17]. It has been shown that IL-12 induces the proliferation of natural killer (NK) cells and T cells, as well as the production of IFN-γ and the activation of cytotoxic T lymphocytes (CTLs) through the STAT4 signaling pathway [@B18], [@B19]. The gene encoding IL-12 is TaqI (A/C) in the 3\'-untranslated region (3\'UTR) at position 1188, which has been found to be associated with several tumors such as nasopharyngeal carcinoma [@B20] and breast cancer [@B21]. This SNP may affect individuals\' susceptibility to glioma.

IL-13 is a Th-2-derived proinflammatory cytokine known to induce apoptosis in many cell types, including glioblastoma multiforme (GBM) [@B22]. The IL-13 gene has many SNPs, which mainly associate with allergy and atopic diseases, as well as effector functions that induce airway hyper-responsiveness, allergic inflammation, immunoglobulin E production, and tumor cell growth [@B23]. Further, high systemic levels of IL-13 are associated with increases in the occurrence in different cancers, including colorectal and ovarian cancer [@B24]. This association is thought to enhance the extracellular-signal-regulated kinase (ERK) and increase transcription factor Ap-1 and matrix metalloproteinase (MMP) activities. Hsi et al. [@B25] found a reduction in glioblastoma multiforme growth in mice after knockdown of IL-13 Rα2 by siRNA, which suggests that IL-13 is a risk factor for this malignancy. Recently, the SNPs for GBM on the polymorphism in exon 4(+2044G/A) have been studied in detail [@B26]. The impact of IL13+2044GA on the functional properties of IL-13 shows that this polymorphism is more active than normal IL-13 in inducing STAT6 phosphorylation and CD23 expression in monocytes and hydrocortisone-dependent IgE switching in B cells [@B27]. Thus, decreased neutralization with carriers of IL13+ 2044A eventually contributes to increased allergic inflammation as a consequence of increased IL-13-mediated Th2 effector function.

Based on current evidence, glioma is a major concern in Iraq. Very little information is available to demonstrate an association between polymorphisms in IL-10-1082A/G, IL-12p40 1188C/A, and IL-13+2044G/A (rs20541) and glioma development and progression. Studying these SNPs may allow us to move forward in developing possible diagnostic and interventional strategies. Accordingly, the present study was designed to investigate the association of SNPs in IL-10, IL-12p40 and IL-13 with the incidence of glioma in Iraqi patients.

Materials and Methods
=====================

Study Population
----------------

This case-control study involved 96 glioma patients (44 male and 52 female, mean age ± 39.18 years) who attended Neuroscience Hospital between January 2013 and March 2014 and 40 (15 male and 25 female, mean age ±37.06 years) apparently healthy individuals. Selection of patients was done with the assistance of surgeons in the hospital. All patients had glioma brain tumors. Data were collected through direct interviews with patients and examination of hospital records and previous medical reports. Patient\'s claims were followed as an alternative source of information when their previous medical reports were not available. The data collected included subjects\' age, gender, smoking habits (never, ex-smoker and current), family history of brain cancer, body mass index, and area of residence. Patients were excluded from the study if they had undergone prior treatment with radiotherapy or chemotherapy or had neuropathology that had not been confirmed as glioma.

Blood Samples
-------------

Two milliliters (ml) of blood were taken from controls and patients before the initiation of chemotherapy or radiation therapy.

DNA Extraction and Genotyping
-----------------------------

DNA was extracted from whole blood samples using a kit (g SYNCTM DNA Mini Kit Whole Blood Protocol, Geneaid, Korea) according to the manufacturer\'s instructions. An amplification- refractory mutation system PCR (ARMS-PCR) was used for amplification and genotyping of IL-10 (-1082 G/A). Allele A was amplified with forward sense primer A (5\'-AACACTAAGGCTTCTTTGGGTA-3\'); allele G was amplified with the primer G (5\'-AACACTACTAAGGCTTCTTTGGGTG-3\'). The common antisense primer (5\'-GTAAGCTTCTGTCGCTGGTGAGTC-3\') was added in both reactions, which amplify allele- specific sequences of 161 bp of the promoter region of IL-10. The cycling conditions involved an initial denaturation at 95ºC for 5 min, followed by 35 cycles at 95ºC for 30 sec, 63ºC for 30 sec, and 72ºC for 30 sec. The final extension step was at 72ºC for 5 min.

Amplification and genotyping of IL-12p40 gene was done using two tubes of sequence- specific primer-PCR (SSP-PCR) with sequence-specific reverse primers 5\'-GTTTCAATGAGCATTTAGCATCT-3\' and 5\'-GTTTCAATGAGCATTTAGCATCTCG-3\' in combination with the consensus forward primer 5\'-ATCTTGGAGCGAATGGGCAT-3\'. Thermo-cycling was done at 95ºC for 2 min, then 35 cycles at 95ºC for 20 sec, 60ºC for 20 sec, and 72ºC for 30 sec, followed by a 5-min final extension at 72ºC. The expected product size was 780 bp. The amplification products were separated by electrophoresis on a 1.5% agarose gel stained with ethidium bromide. The gel was visualized under a UV transluminator with a 100-base-pair ladder. The primer pairs used for amplification of IL-13 were gene-forward primer 5\'-CTTCCGTGAGGACTGAATGAACGGTC-3\' and reverse primer 5\'-GCAAATAATGATGCTTTCGAAGTTTCAGTGGA-3\'. Cycling conditions were 94ºC for 2 min, followed by 30 cycles at 94ºC for 30 sec, 65ºC for 30 sec, 72ºC for 45 sec, and a final extension step of 72ºC for 10 min. This amplification resulted in 236 bp of PCR product.

PCR Product Purification
------------------------

For IL-12p40 PCR product, purification was done using a gSYNCTM PCR Product Purification Mini Kit (Geneaid/Korea) according to the manufacturer\'s instructions.

Measurement of DNA Concentration
--------------------------------

The DNA concentration of purified PCR products was measured using Nanodrop/UVS-99 (ACTGene; Piscataway, NJ USA). All products had a concentration of more than 100 ng/mL and sequenced DNA.

DNA Sequencing
--------------

Polymerase chain reaction products of the IL-13 gene were sent to Bioneer Company (Korea) for DNA sequencing. The obtained sequences, aligned using ClustalW software (Accession Number NC_000005-10) with a normal sequence from GenBank (National Center of Biotechnology Information), were examined for the presence of polymorphisms.

Statistical Analysis
--------------------

The statistical package for social sciences, version 16.0 (SPSS, Chicago) was used for statistical analysis. Chi square test was used to test the deviation from Hardy-Weinberg Equilibrium (HWE) of SNPs by comparing the observed and expected frequencies. The association of different genotypes with the risk of glioma was estimated by calculation of odds ratios (OR) with 95% confidence intervals (CI) using logistic regression. Statistical significance was set at p \<0.05.

Results
=======

Gliomas\' Risk Factors
----------------------

The characteristics of glioma patients as compared to normal healthy controls are shown in Table [1](#T1){ref-type="table"}. Among the studied risk factors, residence showed a significant association with the incidence of glioma, with 60.42% of patients and 40% of controls coming from urban areas (OR= 0.437, 95% CI= 0.206-0.928). Thus, environmental factors may increase individuals\' susceptibility to glioma. No other risk factors had any association with glioma.

Association of IL-10 (-1082A/G) with Gliomas
--------------------------------------------

Genotyping of IL-10 -1082 A/G revealed three genotypes: AA, AG, and GG, which, respectively, had frequencies of 75%, 22.93% and 2.07% among patients and 62.5%, 27.5% and 10% respectively among controls. Despite these variations in percentages, the differences were not significant. However, at the allele level, a chi-square test demonstrated that the mutant allele (G) had a significant protective effect against glioma, with 13.54% of patients and 23.75% of controls having this allele (OR = 0.503, 95% CI = 0.260-0.973) (Fig. [1](#F1){ref-type="fig"}, Table [2](#T2){ref-type="table"}).

Association of IL-12p40 1188A/C with Glioma
-------------------------------------------

SNP IL-12p40 1188A/C also had three genotypes: AA, AC, and CC, which, respectively, accounted for 72.92%, 23.96%, and 3.13% of alleles among patients and 65%, 30% and 5% among controls (Fig. [2](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}). The mutant allele (allele C) frequency was 15.1% among patients and 20% among controls. Neither genotypes nor allele frequencies differed significantly in patients as compared to control subjects. Therefore, the variant IL-12p40 1188A/C may be not considered a risk factor for glioma.

Association of IL-13 +2044G/A with Glioma
-----------------------------------------

IL-13 +2044G/A showed a highly significant association with glioma at both genotype and allele levels. Specifically, 9.37% of glioma patients had the GA genotype as compared to 32.5% of controls (OR = 0.028, 95% CI = 0.003-0.234), while only 1.04% of patients had the AA genotype as compared to 20% of control subjects (OR = 0.181, 95% CI = 0.019-1.706) (Fig. [3](#F3){ref-type="fig"}, Table [2](#T2){ref-type="table"}). Analysis of allele frequency confirmed this result, with allele A occurring in 5.73% of patients and 36.25% of controls (OR = 0.107, 95% CI = 0.050-0.229). Using ClustalW software for multiple sequence alignment showed that the sequence region of the IL-13 gene was identical to that of NCBI (Accession Number NC_000005-10) except in samples having the G nucleotide instead of A at the position 132660272(5q31) on chromosome 5 (Fig. [4](#F4){ref-type="fig"}).

Discussion
==========

Molecular studies suggest that genetic susceptibility may be pivotal in modifying the risk of glioma. Previous studies clearly indicate a candidate gene that encodes for cytokines that regulate immune responses. Genes for DNA repair proteins have also been extensively studied [@B28]. Our study showed significant protective associations against glioma between both allele A of the variant IL-13+2044G/A and allele G of the variant IL-10 (-1082A/G). IL-12p40 1188A/C did not show any association with glioma.

IL-10 is an important cytokine that favors Th2 activity and the humeral arm of adaptive the immune response. It has been shown that the IL-10-1082GG genotype causes an increase in IL-10 production [@B29]. Our results indicate that allele G has a protective role against glioma. In the present study, our result with IL-10 (-1082A/G) corresponds with that from other studies regarding the association of this variant with other cancers. It has been shown that the IL-10 1082 AA genotype is associated with significantly increased risk of lymph-node involvement in Chinese women with breast cancer [@B30]. Increased rates of gastric cancer have also been shown in Chinese people who carry this variant [@B11]. In contrast, however, a previous study regarding the association of SNP with various cancers did not find any effect of IL-10 (-1082A/G) on susceptibility to cervical cancer among Tunisian women [@B31]. It is possible that this discrepancy is be related to allergy and IgE production by these patients.

Recent studies from Brazil and Saudi Arabia have shown an association between allele G (either heterozygous or homozygous) and increased serum levels of IgE [@B32], [@B33]. This finding is corroborated by the results of a meta-analysis involving 2,215 asthma patients and 2,170 controls, which confirmed the association of the G allele with asthma [@B34]. Systemic administration of IL-10 induced an effective, specific, and prolonged immune response against established tumors in mice [@B35], indicating the immune-regulatory rather than immune-suppressive effect of this cytokine. In addition, IL-10 was shown to have an anti-inflammatory effect by suppressing monocyte or macrophage function. Thus, it is one of the main predisposing factors for cancer of chronic inflammation [@B36].

Un-translated regions of genes are involved in the posttranscriptional regulation of gene expression by the modulation of mRNA stability, nucleo‐cytoplasm transport, subcellular localization, and translation efficiency. Thus, these un-translated regions consent the fine control of protein product [@B37]. SNPs in these regions may therefore affect the quantity and quality of the protein encoded by the gene involving these regions. The SNP in IL-12p40 1188A/C may affect IL-12 expression because of its location in the 3\'UTR of IL-12 gene. A contradictory view on correlation between this SNP and increased IL-12 secretion [@B38], [@B39] has been shown in the past. In the present study, neither mutant genotypes (hetero or homozygous) nor mutant allele of the variant IL-12p40 1188A/C appeared to be associated with gliomas. This result is in accordance with a meta-analysis study [@B40]. Although these authors found significant association of the variant with overall cancer, the stratification by cancer type revealed that the variant represents risk factor for cervical and nasopharyngeal cancer only. Taken together, increase in IL-12 production seems to have no effect on the susceptibility to gliomas may be due to the presence of other factors that can interfere with this overproduction.

The murine IL-13 receptor α 1 and 2 has been cloned and characterized in detail by [@B41]. The result from this study clearly suggests that IL-13Rα2 and -α1 are functionally not equal and play a distinct role for each polypeptide in IL-13R complex formation and ultimately modify IL-13 signal transduction. It has been shown that substitution of arginine with neutral glutamine renders IL-13 binds less tightly to the decoy receptor and escapes the dampening mechanisms that normally restrain the activity of wild type IL-13 *in-vivo* [@B27]. This evasion increases the availability of IL-13, which can binds with IL-13Rα2 and IL-4Rα1/IL-13Rα1 heterodimer (the other receptor for IL-13) on APCs and other body cells. Further, it has been shown in same study that IL-13 R130Q is more active than wild type IL-13 in inducing STAT6 phosphorylation and in up-regulation of CD23 in monocytes, which implies an increase in IgE class switching [@B27]. In correspondence with this many previous study confirms the association of this SNP with high serum levels of IgE [@B42], asthma [@B43], atopy and atopic dermatitis [@B44] but not with glioblastoma [@B45]. To this end highly protective role for the variant IL-13+2044 G/A against glioma was recorded in the present study. Similarly, anti-proliferative effect of IL-13 on human solid tumors that inhibit their clonal growth and DNA synthesis is shown [@B46]. In contrast to this most previous studies involving this variants recorded null result for its association with different cancers such as head and neck carcinoma [@B47] and lung cancer [@B48]. Nevertheless a recent meta-analysis study suggests the possibility of IL-13+rs1800925 genotype as a risk factor for gliomas and IL-13+rs20541 contributes towards cancer [@B49]. Further, another recent study on Iranian patient shows that SNPs in IL-13 linked with multiple sclerosis [@B50].

The inverse correlation between different kinds of allergic conditions and the incidence of gliomas was well established in many previous works. For example, high levels of IgE were found among control than glioma patients [@B51], and a strong relationship between these levels and survival rate of glioma patients [@B52]. However, the underlined relationship in this protection role and whether IgE itself has anti-tumor activity on glioma cells or on other cells adjacent to the tumor is not clear. Nevertheless, a recent study reported that stimulation of CD23 expression on astrocytes (through binding with IgE) could induce production of nitric oxide and IL-1β to facilitate cells death by apoptosis [@B53].

To our knowledge, this is the first study in Iraq, which investigated the association of IL-13, IL-10 and IL-12p40 polymorphism and glioma. The results from the present study suggest that SNPs in IL-13 and IL-10 have a protective role against glioma through induction of an allergic status. However, more detailed studies in relation to allergic status are required for this conclusion and involving more SNPs in different cytokine genes are warranted for prudent conclusion.
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![Gel electrophoresis visualized under UV light of IL-10 (-1082 G/A) using ARMS-PCR. Lanes 1-6 control; lane 7, 100 bp DNA marker; lanes 8-13 from glioma patients. In this we used two tubes for each sample and each tube contain one allele. Thus each two wells in the agarose refer to one sample.](ijmsv12p0790g001){#F1}

![Gel electrophoresis visualized under UV light of IL-12p401188A/C after SSP-PCR. Lanes 1-6 control; lane 7, 100 bp DNA marker; lanes 8-11 from glioma patients. In this we used two tubes for each sample and each tube contain one allele. Thus each two wells in the agarose refer to one sample.](ijmsv12p0790g002){#F2}

![DNA sequencing for part of the fourth exon of *IL-13.* The arrow indicates the position of the SNP*IL-13+2044*.A: represents the genotype GG; B: AA and C: AG.](ijmsv12p0790g003){#F3}

![Multiple sequence alignment of IL-13+2044 A/G. The obtained sequence was compared with that of National Center of Biotechnology Information (NCBI).](ijmsv12p0790g004){#F4}

###### 

Association of risk factors with the incidence of glioma

  -------------------------------------------------------------------------------------
  Risk Factors            Cases\        Control\     *P*-value   OR (95%CI)
                          N=96          N=40                     
  ----------------------- ------------- ------------ ----------- ----------------------
  Mean age ± SD (years)   39.18±8.74    37.06±9.11   0.229       1.038 (0.977- 1.104)

  **Gender**                                         0.372       

  Male                    44 (45.83%)   15 (37.5%)               1.0

  Female                  52 (54.17%)   25 (62.5%)               0.709 (0.333-1.510)

  **Family history**                                 0.396       

  No                      84 (87.5%)    37 (92.5%)               1.0

  Yes                     12 (12.5%)    3(7.5%)                  1.762 (0.469-6.615)

  Mean BMI ±SD            26.44±4.27    24.71±5.02   0.077       1.108 (0.989- 1.243)

  **Smoking**                                                    

  Never                   63 (65.63%)   18 (45%)     0.123       1.0

  Ex-smoker               18 (18.75%)   13 (32.5%)   0.108       3.342 (0.766-14.57)

  Current                 15(15.62%)    9 (22.5%)    0.886       1.116(0.247-5.048)

  **Residency**                                      0.029       

  Urban                   58 (60.42%)   16 (40%)                 1.0

  Rural                   38 (39.58%)   24 (60%)                 0.437 (0.206- 0.928)
  -------------------------------------------------------------------------------------

(BMI, body mass index; CI, confidence interval; N, number; OR, odds ratio; SD: standard deviation)

###### 

Distribution of genotypes and allele frequencies of IL-10 (-1082 A/G), IL-12p40 1188A/C, and IL-13+2044G/A in glioma patients and control subjects.

  Variables             Cases (N=96)   Control (N=40)   *P*-value   OR (95%CI)
  --------------------- -------------- ---------------- ----------- ---------------------
  *IL-10 (-1082 AlG)*                                               
  AA                    72 (75%)       25 (62.5%)       0.126       1.0
  AG                    22 (22.93%)    11 (27.5%)       0.051       0.174 (0.030-1.006)
  GG                    2 (2.07%)      4 (10%)          0.141       0.250 (0.039-1.582)
  Alleles                                                           
  A                     166 (86.46%)   61 (76.25%)                  1.0
  *G*                   26 (13.54%)    22 (23.75%)      0.039       0.503 (0.260-0.973)
  *IL-12p40 1188A/C)*                                               
  AA                    70(72.92%)     26 (65%)         0.633       1.0
  AC                    23 (23.96%)    12 (30%)         0.534       0.557 (0.088-3.525)
  CC                    3 (3.13%)      2 (5%)           0.802       0.783 (0.115-5.341)
  Alleles                                                           
  A                     163 (84.9%)    64 (80%)                     1.0
  C                     29 (15.1%)     16(20%)          0.322       0.712(0.362-1.398)
  *IL-13 +2044G/A*                                                  
  GG                    86(89.58%)     19 (47.5%)       0.001       1.0
  GA                    9 (9.37%)      13 (32.5%)       0.001       0.028(0.003-0.234)
  AA                    1 (1.04%)      8 (20%)          0.135       0.181(0.019-1.706)
  Allele                                                            
  G                     181 (94.27%)   51 (63.75%)                  1.0
  A                     11 (5.73%)     29 (36.25%)      0.001       0.107(0.050-0.229)
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